ArticleBritish journal of cancer2009
Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival.
Article in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 72 citations in OpenAlex.
- Molecular Determinants of Receptor-Specific Membrane Interactions in EphA1 and EphA2 from Coarse-Grained Simulations.Journal of chemical information and modeling · 2026Article
- Combined vitamins D3 and K2 as potential modulators of multiple myeloma cell pathophysiology: transcriptomic and epigenetic effects under standard culture and bone marrow-like conditions.Frontiers in oncology · 2026Article
- Potential role of the Eph/ephrin system in colorectal cancer: emerging druggable molecular targets.Frontiers in oncology · 2024Review
- Review
- Eph Receptors in Cancer.Biomedicines · 2023Review
- The EPH/Ephrin System in Colorectal Cancer.International journal of molecular sciences · 2022Review
- Integrated Metabonomics and Network Pharmacology to Reveal the Action Mechanism Effect of Shaoyao Decoction on Ulcerative Colitis.Drug design, development and therapy · 2022Article
- The Clinical Impact of the EPH/Ephrin System in Cancer: Unwinding the Thread.International journal of molecular sciences · 2021Review
- The Role of the Eph Receptor Family in Tumorigenesis.Cancers · 2021Review
- The Effect of Alzheimer's Disease-Associated Genetic Variants on Longevity.Frontiers in genetics · 2021Article
- Evaluation of the Anti-Tumor Activity of Small Molecules Targeting Eph/Ephrins in APCPharmaceuticals (Basel, Switzerland) · 2020Article
- Association Between EphA1 and Tumor Microenvironment in Gastric Carcinoma and its Clinical Significance.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers.Cancers · 2019Article
- Silencing ofOncology letters · 2019Article
- Genetic characterization of thymoma.Scientific reports · 2019Article
- Identification of a 6-gene signature predicting prognosis for colorectal cancer.Cancer cell international · 2019Article
- Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers.BioMed research international · 2018Review
- A review on Eph/ephrin, angiogenesis and lymphangiogenesis in gastric, colorectal and pancreatic cancers.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2017Article
- High expression of EphA4 is associated with invasion and lymph node metastasis in colorectal carcinomas.International journal of clinical and experimental pathology · 2017Article
- Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model.Nature materials · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant expression of Eph and ephrin proteins has well-established functions in oncogenesis and tumour progression. We describe EphA1 expression in 6 colorectal cancer (CRC) cell lines, 18 controls and 125 CRC specimens. In addition, a well-characterised cohort of 53 paired normal colon and CRCs was also assessed. Expression of EphA1 mRNA was assessed by quantitative real-time PCR and correlated with protein expression by flow cytometry, immunoprecipitation, western blotting and immunohistochemistry. Significant upregulation (2- to 10-fold) of EphA1 was seen in over 50% of cases (P=0.005) whereas many of the remainder showed downregulation of EphA1. Intriguingly, EphA1 over-expression was more prevalent in stage II compared to stage III CRCs (P=0.02). Low EphA1 expression significantly correlated with poor survival (P=0.02). Epigenetic silencing appeared to explain the loss of EphA1 expression as methylation of the EphA1 CpG island strongly correlated with low EphA1 expression (P<0.01). Furthermore, EphA1 re-expression could be induced by treatment with demethylating agents. Our findings identify EphA1 as a potential prognostic marker in CRC. Although therapies targeting high EphA1 expression seem plausible in CRC, the loss of expression in advanced disease suggests a potential risk that targeted therapy, by selecting for loss of expression, might contribute to disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.